董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Charles P. Theuer | 男 | Director | 59 | 7.22万美元 | 未持股 | 2023-04-27 |
| Robert J. Wills | 男 | Director,Executive Chairman | 69 | 6.82万美元 | 未持股 | 2023-04-27 |
| Jill DeSimone | 女 | Director | 67 | 未披露 | 未持股 | 2023-04-27 |
| Xin Nakanishi | 女 | Director | 61 | 6.82万美元 | 未持股 | 2023-04-27 |
| James B. Breitmeyer | 男 | Director, President and Chief Executive Officer | 69 | 240.79万美元 | 未持股 | 2023-04-27 |
| William R. LaRue | 男 | Director | 72 | 8.02万美元 | 未持股 | 2023-04-27 |
| Rosemary Mazanet | 女 | Director | 66 | 7.22万美元 | 未持股 | 2023-04-27 |
| Michael G. Carter | 男 | Director | 85 | 9.02万美元 | 未持股 | 2023-04-27 |
| David F. Hale | 男 | Chairman of Board | 74 | 12.68万美元 | 未持股 | 2023-04-27 |
| Daniel L. Kisner | 男 | Director | 76 | 8.07万美元 | 未持股 | 2023-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chase C. Leavitt | 男 | General Counsel and Secretary | 41 | 未披露 | 未持股 | 2023-04-27 |
| Gunnar F. Kaufmann | -- | Chief Scientific Officer | 47 | 94.12万美元 | 未持股 | 2023-04-27 |
| Salim Yazji | 男 | Chief Medical Officer | 54 | 96.25万美元 | 未持股 | 2023-04-27 |
| Rajesh Krishnan | 男 | Chief Technology Officer | 50 | 未披露 | 未持股 | 2023-04-27 |
| James B. Breitmeyer | 男 | Director, President and Chief Executive Officer | 69 | 240.79万美元 | 未持股 | 2023-04-27 |
| Richard G. Vincent | 男 | Chief Financial Officer and Treasurer | 60 | 未披露 | 未持股 | 2023-04-27 |
董事简历
中英对照 | 中文 | 英文- Charles P. Theuer
-
Charles P. Theuer，2006年7月起，担任本公司的总裁、首席执行官、董事。2004-2006，他是生物技术公司TargeGen, Inc的首席医学官、临床开发副总裁。加入TargeGen, Inc之前，2003-2004，他担任制药公司Pfizer, Inc的临床肿瘤学总监。2003-2004，2002-2003，他分别在IDEC Pharmaceuticals Corp.、National Cancer Institute担任过多个职务。另外，他在University of California, Irvine担任过学术职位，曾是肿瘤外科、医学系的副教授。他在Massachusetts Institute of Technology获得学士学位，在University of California, San Francisco获得医学博士学位，在University of California, Irvine获得博士学位；在Harbor-UCLA Medical Center完成普通外科驻院实习，于1997年通过普通外科专家认证。
Charles P. Theuer has served as Tracon Pharmaceuticals, Inc. President, Chief Executive Officer and a member of Tracon Pharmaceuticals, Inc. Board since July 2006. From 2004 to 2006 Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016 and also serves as a director at Oncternal Therapeutics, Inc., a position he has held since 2018. - Charles P. Theuer，2006年7月起，担任本公司的总裁、首席执行官、董事。2004-2006，他是生物技术公司TargeGen, Inc的首席医学官、临床开发副总裁。加入TargeGen, Inc之前，2003-2004，他担任制药公司Pfizer, Inc的临床肿瘤学总监。2003-2004，2002-2003，他分别在IDEC Pharmaceuticals Corp.、National Cancer Institute担任过多个职务。另外，他在University of California, Irvine担任过学术职位，曾是肿瘤外科、医学系的副教授。他在Massachusetts Institute of Technology获得学士学位，在University of California, San Francisco获得医学博士学位，在University of California, Irvine获得博士学位；在Harbor-UCLA Medical Center完成普通外科驻院实习，于1997年通过普通外科专家认证。
- Charles P. Theuer has served as Tracon Pharmaceuticals, Inc. President, Chief Executive Officer and a member of Tracon Pharmaceuticals, Inc. Board since July 2006. From 2004 to 2006 Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer currently serves as a director at 4D Molecular Therapeutics, a position he has held since January 2016 and also serves as a director at Oncternal Therapeutics, Inc., a position he has held since 2018.
- Robert J. Wills
-
Robert J. Wills，于2015年3月加入Oncternal Therapeutics, Inc.董事会担任执行主席，并自2019年6月合并完成以来一直担任Oncternal Therapeutics, Inc.董事会成员。Wills还担任CymaBay Therapeutics的董事会主席、Milestone Pharmaceuticals的董事会主席、Parion Sciences的董事会成员、Go Therapeutics的董事会成员和Feldan Therapeutics的董事会成员。在担任这些职务之前，他在Johnson & Johnson公司工作了超过25年。最近，他担任Johnson & Johnson的Janssen Pharmaceutical Companies的联盟管理副总裁。他还担任全球发展高级副总裁，负责研发管道和研发董事会成员。此外，他曾在几个商业运营公司董事会和关键制药集团决策委员会任职。他在Hoffmann-LaRoche开始了他的职业生涯，在那里他花了10年时间担任多个科学责任角色。他持有the University of Wisconsin的生物化学学士学位和药剂学硕士学位，以及the University of Texas的药剂学博士学位。
Robert J. Wills,joined Oncternal Therapeutics, Inc. board as the Executive Chairman in March 2015, and has served as a member of Oncternal Therapeutics, Inc. board since the completion of the Merger in June 2019.Dr. Wills also serves as Chairman of the Board of CymaBay Therapeutics, as Chairman of the Board at Milestone Pharmaceuticals, Inc., as board member at Parion Sciences, Inc., as board member at Go Therapeutics and as a board member of Feldan Therapeutics. Prior to these roles, Dr. Wills spent over 25 years at Johnson & Johnson. Most recently he was Vice President, Alliance Management, Janssen Pharmaceutical Companies of Johnson & Johnson. He also served as Senior Vice President Global Development, where he was responsible for the R&D pipeline and a member of the R&D Board of Directors. In addition, he served on several of the commercial Operating Company Boards and key pharmaceutical group decision-making committees. Dr. Wills began his career at Hoffmann-LaRoche where he spent 10 years in several roles of scientific responsibility. He holds a BS in Biochemistry and an MS in Pharmaceutics from the University of Wisconsin and a PhD in Pharmaceutics from the University of Texas. - Robert J. Wills，于2015年3月加入Oncternal Therapeutics, Inc.董事会担任执行主席，并自2019年6月合并完成以来一直担任Oncternal Therapeutics, Inc.董事会成员。Wills还担任CymaBay Therapeutics的董事会主席、Milestone Pharmaceuticals的董事会主席、Parion Sciences的董事会成员、Go Therapeutics的董事会成员和Feldan Therapeutics的董事会成员。在担任这些职务之前，他在Johnson & Johnson公司工作了超过25年。最近，他担任Johnson & Johnson的Janssen Pharmaceutical Companies的联盟管理副总裁。他还担任全球发展高级副总裁，负责研发管道和研发董事会成员。此外，他曾在几个商业运营公司董事会和关键制药集团决策委员会任职。他在Hoffmann-LaRoche开始了他的职业生涯，在那里他花了10年时间担任多个科学责任角色。他持有the University of Wisconsin的生物化学学士学位和药剂学硕士学位，以及the University of Texas的药剂学博士学位。
- Robert J. Wills,joined Oncternal Therapeutics, Inc. board as the Executive Chairman in March 2015, and has served as a member of Oncternal Therapeutics, Inc. board since the completion of the Merger in June 2019.Dr. Wills also serves as Chairman of the Board of CymaBay Therapeutics, as Chairman of the Board at Milestone Pharmaceuticals, Inc., as board member at Parion Sciences, Inc., as board member at Go Therapeutics and as a board member of Feldan Therapeutics. Prior to these roles, Dr. Wills spent over 25 years at Johnson & Johnson. Most recently he was Vice President, Alliance Management, Janssen Pharmaceutical Companies of Johnson & Johnson. He also served as Senior Vice President Global Development, where he was responsible for the R&D pipeline and a member of the R&D Board of Directors. In addition, he served on several of the commercial Operating Company Boards and key pharmaceutical group decision-making committees. Dr. Wills began his career at Hoffmann-LaRoche where he spent 10 years in several roles of scientific responsibility. He holds a BS in Biochemistry and an MS in Pharmaceutics from the University of Wisconsin and a PhD in Pharmaceutics from the University of Texas.
- Jill DeSimone
-
Jill DeSimone，自2022年5月起担任Praxis Precision Medicines, Inc.董事会成员。2014年至2022年5月，DeSimone女士在默克公司（Merck & Co.，Inc.）担任美国肿瘤学总裁。在默克公司任职期间，DeSimone女士还曾临时担任美国制药公司的临时总裁，以帮助公司度过新冠疫情。在加入默克公司之前，她曾于2012年至2014年在梯瓦制药工业有限公司（Teva Pharmaceutical Industries Ltd）担任全球妇女健康高级副总裁。在加入Teva公司之前，DeSimone女士曾于1980年至2012年在百时美施贵宝公司担任多个职务，包括肿瘤学高级副总裁和商业运营高级副总裁。DeSimone女士在Oncternate Therapeutics（纳斯达克股票代码：ONCT）、Kinnate Biopharma Inc.（纳斯达克股票代码：KNTE）和Affini-T Therapeutics，Inc.（一家私营公司）担任董事会董事，自2023年3月1日起生效。她还担任佛罗里达癌症专家基金会的董事会成员，该基金会是一个非营利组织，帮助个人在接受癌症治疗期间支付必要的生活费用。DeSimone女士获得了东北大学的药学学士学位，并获得了宾夕法尼亚大学沃顿商学院的奖学金。我们相信DeSimone女士有资格担任董事会成员，因为她在制药行业具有领导能力和丰富的商业经验。
Jill DeSimone,has served as a member of Praxis Precision Medicines, Inc. Board of Directors since May 2022. Ms. DeSimone served as President of U.S. Oncology at Merck & Co., Inc., or Merck, from 2014 to May 2022. During her time at Merck, Ms. DeSimone also temporarily served as Interim President of U.S. Pharma to help navigate the business through the COVID-19 pandemic. Prior to joining Merck, she served as Senior Vice President of Global Women's Health at Teva Pharmaceutical Industries Ltd, or Teva, from 2012 to 2014. Prior to her time at Teva, Ms. DeSimone served in several roles of increasing responsibility at Bristol Myers Squibb from 1980 to 2012, including Senior Vice President of Oncology and Senior Vice President of Commercial Operations. Ms. DeSimone serves on the board of directors of Oncternal Therapeutics (NASDAQ: ONCT), Kinnate Biopharma Inc. (NASDAQ: KNTE), effective March 1, 2023, and Affini-T Therapeutics, Inc., a private company. She also serves as a board member for the Florida Cancer Specialists Foundation, a nonprofit organization that helps individuals with their essential living expenses while they undergo treatment for cancer. Ms. DeSimone received a B.S. in pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania. - Jill DeSimone，自2022年5月起担任Praxis Precision Medicines, Inc.董事会成员。2014年至2022年5月，DeSimone女士在默克公司（Merck & Co.，Inc.）担任美国肿瘤学总裁。在默克公司任职期间，DeSimone女士还曾临时担任美国制药公司的临时总裁，以帮助公司度过新冠疫情。在加入默克公司之前，她曾于2012年至2014年在梯瓦制药工业有限公司（Teva Pharmaceutical Industries Ltd）担任全球妇女健康高级副总裁。在加入Teva公司之前，DeSimone女士曾于1980年至2012年在百时美施贵宝公司担任多个职务，包括肿瘤学高级副总裁和商业运营高级副总裁。DeSimone女士在Oncternate Therapeutics（纳斯达克股票代码：ONCT）、Kinnate Biopharma Inc.（纳斯达克股票代码：KNTE）和Affini-T Therapeutics，Inc.（一家私营公司）担任董事会董事，自2023年3月1日起生效。她还担任佛罗里达癌症专家基金会的董事会成员，该基金会是一个非营利组织，帮助个人在接受癌症治疗期间支付必要的生活费用。DeSimone女士获得了东北大学的药学学士学位，并获得了宾夕法尼亚大学沃顿商学院的奖学金。我们相信DeSimone女士有资格担任董事会成员，因为她在制药行业具有领导能力和丰富的商业经验。
- Jill DeSimone,has served as a member of Praxis Precision Medicines, Inc. Board of Directors since May 2022. Ms. DeSimone served as President of U.S. Oncology at Merck & Co., Inc., or Merck, from 2014 to May 2022. During her time at Merck, Ms. DeSimone also temporarily served as Interim President of U.S. Pharma to help navigate the business through the COVID-19 pandemic. Prior to joining Merck, she served as Senior Vice President of Global Women's Health at Teva Pharmaceutical Industries Ltd, or Teva, from 2012 to 2014. Prior to her time at Teva, Ms. DeSimone served in several roles of increasing responsibility at Bristol Myers Squibb from 1980 to 2012, including Senior Vice President of Oncology and Senior Vice President of Commercial Operations. Ms. DeSimone serves on the board of directors of Oncternal Therapeutics (NASDAQ: ONCT), Kinnate Biopharma Inc. (NASDAQ: KNTE), effective March 1, 2023, and Affini-T Therapeutics, Inc., a private company. She also serves as a board member for the Florida Cancer Specialists Foundation, a nonprofit organization that helps individuals with their essential living expenses while they undergo treatment for cancer. Ms. DeSimone received a B.S. in pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania.
- Xin Nakanishi
-
Xin Nakanishi，自2019年6月合并完成以来一直担任Oncternal医疗公司董事会成员，自2018年11月起担任Private Oncternal公司董事会成员。她自2018年7月起担任上海医药控股有限公司（“SPH”）子公司上海医药生物治疗美国公司（“SPHbio”）首席执行官，自2021年3月起担任SPHbio董事会成员。自2022年8月起，中西博士还担任Lionel Therapeutics，Inc.的董事。Nakanishi博士曾于2017年至2018年担任元生生物风险投资公司的风险合伙人，并于2009年至2018年担任Sunvita Therapeutics，LLC的首席执行官和创始人，该公司为多家美国和中国生物制药公司提供跨境业务发展。她还是Phenomix公司的生物学主任，辉瑞的高级科学家，Immusol公司的组长。Nakanishi博士拥有武汉大学的病毒学学士学位和堪萨斯大学的生物化学博士学位。
Xin Nakanishi,has served as a member of Oncternal Therapeutics, Inc. board of directors since the completion of the Merger in June 2019, and as a member of the board of directors of Private Oncternal since November 2018. She has served as the Chief Executive Officer of Shanghai Pharma Biotherapeutics USA Inc. ("SPHbio"), a subsidiary of Shanghai Pharmaceuticals Holding Co. Ltd. ("SPH"), since July 2018 and as a member of the board of directors of SPHbio since March 2021. Dr. Nakanishi also serves as a director of Lionel Therapeutics, Inc. since August 2022. Dr. Nakanishi previously served as a venture partner at Yuansheng BioVenture from 2017-2018, and was CEO and founder of Sunvita Therapeutics, LLC from 2009-2018, a company that provided cross border business development for various U.S. and Chinese biopharmaceutical companies. She was also the Director of Biology at Phenomix Inc., a senior scientist at Pfizer, and a group leader at Immusol Inc. Dr. Nakanishi holds a B.A. in Virology from Wuhan University and a Ph.D. in Biochemistry from the University of Kansas. - Xin Nakanishi，自2019年6月合并完成以来一直担任Oncternal医疗公司董事会成员，自2018年11月起担任Private Oncternal公司董事会成员。她自2018年7月起担任上海医药控股有限公司（“SPH”）子公司上海医药生物治疗美国公司（“SPHbio”）首席执行官，自2021年3月起担任SPHbio董事会成员。自2022年8月起，中西博士还担任Lionel Therapeutics，Inc.的董事。Nakanishi博士曾于2017年至2018年担任元生生物风险投资公司的风险合伙人，并于2009年至2018年担任Sunvita Therapeutics，LLC的首席执行官和创始人，该公司为多家美国和中国生物制药公司提供跨境业务发展。她还是Phenomix公司的生物学主任，辉瑞的高级科学家，Immusol公司的组长。Nakanishi博士拥有武汉大学的病毒学学士学位和堪萨斯大学的生物化学博士学位。
- Xin Nakanishi,has served as a member of Oncternal Therapeutics, Inc. board of directors since the completion of the Merger in June 2019, and as a member of the board of directors of Private Oncternal since November 2018. She has served as the Chief Executive Officer of Shanghai Pharma Biotherapeutics USA Inc. ("SPHbio"), a subsidiary of Shanghai Pharmaceuticals Holding Co. Ltd. ("SPH"), since July 2018 and as a member of the board of directors of SPHbio since March 2021. Dr. Nakanishi also serves as a director of Lionel Therapeutics, Inc. since August 2022. Dr. Nakanishi previously served as a venture partner at Yuansheng BioVenture from 2017-2018, and was CEO and founder of Sunvita Therapeutics, LLC from 2009-2018, a company that provided cross border business development for various U.S. and Chinese biopharmaceutical companies. She was also the Director of Biology at Phenomix Inc., a senior scientist at Pfizer, and a group leader at Immusol Inc. Dr. Nakanishi holds a B.A. in Virology from Wuhan University and a Ph.D. in Biochemistry from the University of Kansas.
- James B. Breitmeyer
-
James B. Breitmeyer，2006年8月起，担任本公司的开发执行副总裁、首席医学官。2001年12月至2006年8月，他担任Applied Molecular Evolution的首席医学官、制药业务副总裁，这是全球性制药公司Eli Lilly and Company的全资子公司。2000年2月至2001年7月，他是Harvard Clinical Research Institute的总裁、首席执行官。2000年2月之前，他在全球性生物制药公司Serono International S.A.担任了愈益重要的各种职务，其中包括高级副总裁、首席医学官。他在University of California, Santa Cruz获得化学学士学位，在Washington University School of Medicine获得医学博士学位、博士学位。
James B. Breitmeyer, M.D., Ph.D. has served as a member of ZOGENIX, INC. board of directors since March 2014. Since August 2015 Dr. Breitmeyer has served as President, CEO and Director of Oncternal Therapeutics, Inc. a clinical-stage oncology biotechnology company. Previously, he served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian A/S, a multinational corporation headquartered in Denmark, from February 2013 to July 2015. He previously served as the acting Chief Medical Officer of Zogenix Inc. from August 2012 to February 2013 in an advisory capacity, the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., from August 2006 to August 2012 and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. from December 2001 to August 2006. Dr. Breitmeyer has also served as President and Chief Executive Officer of the Harvard Clinical Research Institute and held a variety of positions at Serono Laboratories Inc. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer earned his B.A. in Chemistry from the University of California, Santa Cruz and his M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology. - James B. Breitmeyer，2006年8月起，担任本公司的开发执行副总裁、首席医学官。2001年12月至2006年8月，他担任Applied Molecular Evolution的首席医学官、制药业务副总裁，这是全球性制药公司Eli Lilly and Company的全资子公司。2000年2月至2001年7月，他是Harvard Clinical Research Institute的总裁、首席执行官。2000年2月之前，他在全球性生物制药公司Serono International S.A.担任了愈益重要的各种职务，其中包括高级副总裁、首席医学官。他在University of California, Santa Cruz获得化学学士学位，在Washington University School of Medicine获得医学博士学位、博士学位。
- James B. Breitmeyer, M.D., Ph.D. has served as a member of ZOGENIX, INC. board of directors since March 2014. Since August 2015 Dr. Breitmeyer has served as President, CEO and Director of Oncternal Therapeutics, Inc. a clinical-stage oncology biotechnology company. Previously, he served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian A/S, a multinational corporation headquartered in Denmark, from February 2013 to July 2015. He previously served as the acting Chief Medical Officer of Zogenix Inc. from August 2012 to February 2013 in an advisory capacity, the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., from August 2006 to August 2012 and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. from December 2001 to August 2006. Dr. Breitmeyer has also served as President and Chief Executive Officer of the Harvard Clinical Research Institute and held a variety of positions at Serono Laboratories Inc. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer earned his B.A. in Chemistry from the University of California, Santa Cruz and his M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology.
- William R. LaRue
-
William R. LaRue，2014年7月起，担任本公司董事。2006年6月起，他担任生物制药公司Cadence Pharmaceuticals, Inc.的首席财务官、高级副总裁、财务总管，直到2014年3月它被Mallinckrodt plc收购；2007年4月至2014年3月，担任副秘书。加入Cadence之前，2001-2006，他是生物技术公司Micromet, Inc.（原 CancerVax Corporation）的高级副总裁、首席财务官。2000-2001，他担任eHelp Corporation的执行副总裁、首席财务官，这是一个用户协助软件提供商。此前，1997-2000，他是医疗器械公司Safeskin Corporation的副总裁、财务总管；1993-1997，担任高科技电子系统公司GDE Systems, Inc.的财务总管。2008年10月至今，他担任Neurelis, Inc.的董事，这是一个专业制药公司。他在University of Southern California获得工商管理学士学位、工商管理硕士学位。
William R. LaRue has served as a member of Tracon Pharmaceuticals, Inc. Board since July 2014. He served as the Chief Financial Officer, Senior Vice President and Treasurer at Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from June 2006 until its acquisition by Mallinckrodt plc in March 2014 and from April 2007 to March 2014 he served as the Assistant Secretary at Cadence. Prior to joining Cadence Pharmaceuticals, Inc., Mr. LaRue was the Senior Vice President and Chief Financial Officer of Micromet, Inc. formerly CancerVax Corporation, a biotechnology company, from 2001 to 2006. From 2000 to 2001 Mr. LaRue served as the Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software. Previously, he was the Vice President and Treasurer of Safeskin Corporation, a medical device company, from 1997 to 2000 and the Treasurer of GDE Systems, Inc., a high technology electronic systems company from 1993 to 1997. Mr. LaRue currently serves on the board of directors of Conatus Pharmaceuticals, Inc., a position he has held since February 2017. In addition, since December 2017 Mr. LaRue has served on the board of directors of Oncternal Therapeutics, Inc., a cancer therapeutics company that entered into a reverse merger agreement with GTx, Inc. in March 2019 and also serves on the board of directors of Alastin Skincare, Inc., a private innovative skincare company. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California. - William R. LaRue，2014年7月起，担任本公司董事。2006年6月起，他担任生物制药公司Cadence Pharmaceuticals, Inc.的首席财务官、高级副总裁、财务总管，直到2014年3月它被Mallinckrodt plc收购；2007年4月至2014年3月，担任副秘书。加入Cadence之前，2001-2006，他是生物技术公司Micromet, Inc.（原 CancerVax Corporation）的高级副总裁、首席财务官。2000-2001，他担任eHelp Corporation的执行副总裁、首席财务官，这是一个用户协助软件提供商。此前，1997-2000，他是医疗器械公司Safeskin Corporation的副总裁、财务总管；1993-1997，担任高科技电子系统公司GDE Systems, Inc.的财务总管。2008年10月至今，他担任Neurelis, Inc.的董事，这是一个专业制药公司。他在University of Southern California获得工商管理学士学位、工商管理硕士学位。
- William R. LaRue has served as a member of Tracon Pharmaceuticals, Inc. Board since July 2014. He served as the Chief Financial Officer, Senior Vice President and Treasurer at Cadence Pharmaceuticals, Inc., a biopharmaceutical company, from June 2006 until its acquisition by Mallinckrodt plc in March 2014 and from April 2007 to March 2014 he served as the Assistant Secretary at Cadence. Prior to joining Cadence Pharmaceuticals, Inc., Mr. LaRue was the Senior Vice President and Chief Financial Officer of Micromet, Inc. formerly CancerVax Corporation, a biotechnology company, from 2001 to 2006. From 2000 to 2001 Mr. LaRue served as the Executive Vice President and Chief Financial Officer of eHelp Corporation, a provider of user assistance software. Previously, he was the Vice President and Treasurer of Safeskin Corporation, a medical device company, from 1997 to 2000 and the Treasurer of GDE Systems, Inc., a high technology electronic systems company from 1993 to 1997. Mr. LaRue currently serves on the board of directors of Conatus Pharmaceuticals, Inc., a position he has held since February 2017. In addition, since December 2017 Mr. LaRue has served on the board of directors of Oncternal Therapeutics, Inc., a cancer therapeutics company that entered into a reverse merger agreement with GTx, Inc. in March 2019 and also serves on the board of directors of Alastin Skincare, Inc., a private innovative skincare company. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California.
- Rosemary Mazanet
-
Rosemary Mazanet,M.D.,Ph.D于2010年2月19日从董事会正式退休。
Rosemary Mazanet,Since June 2015, Dr. Mazanet has served as the Chair of the Scientific Advisory Board and since September 2017 as Chief Science Officer for Columbia Care, Inc. She is a Director at Oncternal Therapeutics, a Nasdaq-listed company, since January 2021, and private company Angiochem. She has served as Clinical Advisor and interim C-suite management to many companies and funds through her consultancy business, R Mazanet LLC, which she has managed as President since May 2004. Dr. Mazanet also has experience in public equity markets as a Managing Partner at Apelles Investment, LLC from 2007 to 2014, and as the Head of Research at Oracle Partners LP from 1998 to 2004. Prior to her public equity work, Dr. Mazanet worked at Amgen, Inc., where she led Clinical Development teams that conducted successful development programs leading to product approvals. Dr. Mazanet served as a director and member of the audit committee of GTx, Inc., a Nasdaq-listed company, from January 2002 to June 2010 and an independent Director of MasterCell from 2019 to 2020. Both companies were subsequently acquired. Dr. Mazanet has served as a Trustee at the University of Pennsylvania Health System since July 2002, and as the Chair, Executive Advisory Board for the Wharton Leonard Davis Institute since December 2020. Dr. Mazanet holds a B.A. in biology from the University of Virginia, and a Doctor of Medicine degree and a Doctor of Philosophy degree from the University of Pennsylvania. Dr. Mazanet is trained as an internist and oncologist with privileges at the Harvard Hospitals. - Rosemary Mazanet,M.D.,Ph.D于2010年2月19日从董事会正式退休。
- Rosemary Mazanet,Since June 2015, Dr. Mazanet has served as the Chair of the Scientific Advisory Board and since September 2017 as Chief Science Officer for Columbia Care, Inc. She is a Director at Oncternal Therapeutics, a Nasdaq-listed company, since January 2021, and private company Angiochem. She has served as Clinical Advisor and interim C-suite management to many companies and funds through her consultancy business, R Mazanet LLC, which she has managed as President since May 2004. Dr. Mazanet also has experience in public equity markets as a Managing Partner at Apelles Investment, LLC from 2007 to 2014, and as the Head of Research at Oracle Partners LP from 1998 to 2004. Prior to her public equity work, Dr. Mazanet worked at Amgen, Inc., where she led Clinical Development teams that conducted successful development programs leading to product approvals. Dr. Mazanet served as a director and member of the audit committee of GTx, Inc., a Nasdaq-listed company, from January 2002 to June 2010 and an independent Director of MasterCell from 2019 to 2020. Both companies were subsequently acquired. Dr. Mazanet has served as a Trustee at the University of Pennsylvania Health System since July 2002, and as the Chair, Executive Advisory Board for the Wharton Leonard Davis Institute since December 2020. Dr. Mazanet holds a B.A. in biology from the University of Virginia, and a Doctor of Medicine degree and a Doctor of Philosophy degree from the University of Pennsylvania. Dr. Mazanet is trained as an internist and oncologist with privileges at the Harvard Hospitals.
- Michael G. Carter
-
Michael G. Carter， 2006年5月被任命为Oncternal Therapeutics， Inc.董事会成员。此前，Carter博士从2004年到2013年担任Santarus， Inc.的非执行董事，从2001年到2005年担任Micromet AG的非执行董事，从2006年到2012年3月担任Micromet， Inc.的非执行董事，从2005年到2010年担任Fulcrum Pharma， PLC的非执行董事。Carter博士于2005年至2008年担任Paul Capital Royalty Fund顾问委员会成员，并于1998年至2016年担任SV Life Sciences Advisors， LLP的风险合伙人。他曾担任Healthcare Royalty Partners （HCRP）战略顾问委员会成员（2009年9月以来），以及HCRP投资委员会成员（2015年以来）。从1999年到2008年，Carter博士担任Metris Therapeutics，Ltd.（一家专门从事女性医疗保健的生物技术公司）的非执行主席。从2013年6月起，他还担任ONCOETHIX的非执行董事，直到2014年12月将其出售给Merck & Co.。他曾担任AstraZeneca的前身公司I.C.I. Zeneca Pharmaceuticals的制药董事会成员，并于1984年至1998年担任I.C.I. Zeneca的各种职位，包括国际医疗总监和国际营销总监。从1985年到1995年，Carter博士担任英国政府药品委员会的成员。Carter博士是Royal Pharmaceutical Society、Faculty of Pharmaceutical Medicine和Royal College of Physicians of Edinburgh的当选会员。他持有London University（英国）的药剂学学位和SSheffield University Medical School（英国）的医学学位。
Michael G. Carter,was appointed as a member of Oncternal Therapeutics, Inc. board of directors in May 2006. Previously, Dr. Carter was a non-executive director of Santarus, Inc. from 2004 to 2013, served as a non-executive director of Micromet AG from 2001 to 2005 and of MICROMET, Inc. from 2006 to March 2012, and served as a non-executive director of Fulcrum Pharma, PLC from 2005 to 2010. Dr. Carter was a member of the advisory board of Paul Capital Royalty Fund from 2005 to 2008, and was a venture partner with SV Life Sciences Advisors, LLP from 1998 to 2016. He has served as a member of the strategic advisory board of Healthcare Royalty Partners (HCRP) since September 2009 and a member of the HCRP Investment Committee since 2015. Dr. Carter was the non-executive chairman of Metris Therapeutics, Ltd., a biotechnology firm specializing in women's healthcare from 1999 to 2008. He was also a non-executive director of ONCOETHIX from June 2013 until its sale to Merck & Co., in December 2014. Dr. Carter served on the pharmaceutical board of I.C.I. Zeneca Pharmaceuticals, a predecessor company of AstraZeneca, and held various positions with I.C.I. Zeneca from 1984 to 1998, including International Medical Director and International Marketing Director. From 1985 to 1995, Dr. Carter served as a member of the U.K. Government's Medicines Commission. Dr. Carter is an Elected Fellow of the Royal Pharmaceutical Society, Faculty of Pharmaceutical Medicine, and of the Royal College of Physicians of Edinburgh. Dr. Carter holds a degree in pharmacy from London University (U.K.) and a medical degree from Sheffield University Medical School (U.K.). - Michael G. Carter， 2006年5月被任命为Oncternal Therapeutics， Inc.董事会成员。此前，Carter博士从2004年到2013年担任Santarus， Inc.的非执行董事，从2001年到2005年担任Micromet AG的非执行董事，从2006年到2012年3月担任Micromet， Inc.的非执行董事，从2005年到2010年担任Fulcrum Pharma， PLC的非执行董事。Carter博士于2005年至2008年担任Paul Capital Royalty Fund顾问委员会成员，并于1998年至2016年担任SV Life Sciences Advisors， LLP的风险合伙人。他曾担任Healthcare Royalty Partners （HCRP）战略顾问委员会成员（2009年9月以来），以及HCRP投资委员会成员（2015年以来）。从1999年到2008年，Carter博士担任Metris Therapeutics，Ltd.（一家专门从事女性医疗保健的生物技术公司）的非执行主席。从2013年6月起，他还担任ONCOETHIX的非执行董事，直到2014年12月将其出售给Merck & Co.。他曾担任AstraZeneca的前身公司I.C.I. Zeneca Pharmaceuticals的制药董事会成员，并于1984年至1998年担任I.C.I. Zeneca的各种职位，包括国际医疗总监和国际营销总监。从1985年到1995年，Carter博士担任英国政府药品委员会的成员。Carter博士是Royal Pharmaceutical Society、Faculty of Pharmaceutical Medicine和Royal College of Physicians of Edinburgh的当选会员。他持有London University（英国）的药剂学学位和SSheffield University Medical School（英国）的医学学位。
- Michael G. Carter,was appointed as a member of Oncternal Therapeutics, Inc. board of directors in May 2006. Previously, Dr. Carter was a non-executive director of Santarus, Inc. from 2004 to 2013, served as a non-executive director of Micromet AG from 2001 to 2005 and of MICROMET, Inc. from 2006 to March 2012, and served as a non-executive director of Fulcrum Pharma, PLC from 2005 to 2010. Dr. Carter was a member of the advisory board of Paul Capital Royalty Fund from 2005 to 2008, and was a venture partner with SV Life Sciences Advisors, LLP from 1998 to 2016. He has served as a member of the strategic advisory board of Healthcare Royalty Partners (HCRP) since September 2009 and a member of the HCRP Investment Committee since 2015. Dr. Carter was the non-executive chairman of Metris Therapeutics, Ltd., a biotechnology firm specializing in women's healthcare from 1999 to 2008. He was also a non-executive director of ONCOETHIX from June 2013 until its sale to Merck & Co., in December 2014. Dr. Carter served on the pharmaceutical board of I.C.I. Zeneca Pharmaceuticals, a predecessor company of AstraZeneca, and held various positions with I.C.I. Zeneca from 1984 to 1998, including International Medical Director and International Marketing Director. From 1985 to 1995, Dr. Carter served as a member of the U.K. Government's Medicines Commission. Dr. Carter is an Elected Fellow of the Royal Pharmaceutical Society, Faculty of Pharmaceutical Medicine, and of the Royal College of Physicians of Edinburgh. Dr. Carter holds a degree in pharmacy from London University (U.K.) and a medical degree from Sheffield University Medical School (U.K.).
- David F. Hale
-
David F. Hale, 2011年3月被任命为BIOCEPT公司执行董事长。截至2014年2月10日BIOCEPT INC首次公开发行(ipo)完成并与此相关，他曾担任BIOCEPT INC非执行主席至2020年10月。他是Hale BioPharma Ventures LLC(一家专注于生物技术、专业制药、诊断和医疗设备公司的形成和发展的私人公司)的董事长兼首席执行官。他是一名连续企业家，参与了许多生命科学公司的创立和/或发展。自2004年以来，他担任Santarus, Inc.(或Santarus，一家专业生物制药公司)的董事长;自2000年以来，担任Santarus的董事会成员(2014年被Salix Pharmaceuticals, Ltd.收购)。他还曾担任Conatus Pharmaceuticals, Inc.的董事长，直到该公司于2020年与Histogen合并。他曾担任CancerVax Corporation的总裁兼首席执行官(从1999年10月到2006年5月与Micromet, Inc.合并)，当时他成为合并后公司的董事长，直到该公司被Merck & Co.收购。他是Somaxon Pharmaceuticals, Inc.(被Pernix Therapeutics Holdings, Inc.收购)的联合创始人兼董事长，以及SkinMedica, Inc.(被Allergan, Inc.收购)的董事长。他还担任Adigica Health, Inc.、Zerigo Health, Inc.、Neurana Pharmaceuticals, Inc.和Dermata, LLC的董事长，以及Recros Medica, Inc.和Neurelis, Inc.的董事会成员。他曾担任Hybritech, Inc.(第一家单克隆抗体公司，自1982年起被Eli Lilly and Co.收购)的首席运营官、总裁兼首席执行官。从1987年到1997年，他担任Gensia, Inc.(与SICOR合并成为Gensia SICOR, Inc.)的董事长、总裁兼首席执行官，Gensia SICOR, Inc.后来被Teva Pharmaceuticals收购。1987年至1995年，他是Viagene, Inc.的联合创始人兼董事长，当时Viagene被Chiron, Inc.收购。1998年至1999年6月，他担任Women First HealthCare, Inc.的总裁兼首席执行官，1999年10月加入CancerVax。在加入Hybritech之前，他曾担任Becton, Dickinson & Co.的诊断部门BBL Microbiology Systems的副总裁兼总经理，从1971年到1980年，他曾担任Ortho Pharmaceutical Corporation (Johnson & Johnson, Inc.的一个部门)的各种营销和销售管理职位。
David F. Hale was appointed as BIOCEPT INC Executive Chairman in March 2011. As of and in connection with the closing of BIOCEPT INC initial public offering on February 10 2014 Mr. Hale served as BIOCEPT INC non-executive chairman through October 2020. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences companies. He served as the Chairman of Santarus, Inc., or Santarus, a specialty biopharmaceutical company, since 2004 and a member of Santarus' board since 2000 prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014. He also served as Chairman of Conatus Pharmaceuticals, Inc. until its merger with Histogen in 2020 and serves as Chairman of Oncternal Therapeutics, Inc. He was previously President and CEO of CancerVax Corporation from October 1999 through its merger in May 2006 with Micromet, Inc., when he became Chairman of the combined company until its acquisition by Merck & Co. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc., and as Chairman of SkinMedica, Inc., before its acquisition by Allergan, Inc. He also serves as Chairman of Adigica Health, Inc., Zerigo Health, Inc., Neurana Pharmaceuticals, Inc., and Dermata, LLC and is on the board of Recros Medica, Inc. and Neurelis, Inc. He served as COO, President and Chief Executive Officer of Hybritech, Inc., the first monoclonal antibody company, from 1982 it was acquired by Eli Lilly and Co. in 1986. From 1987 until 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was later acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995 when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc. from 1998 to June 1999 before joining CancerVax in October 1999. Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a diagnostics division of Becton, Dickinson & Co. and from 1971 to 1980 he held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. - David F. Hale, 2011年3月被任命为BIOCEPT公司执行董事长。截至2014年2月10日BIOCEPT INC首次公开发行(ipo)完成并与此相关，他曾担任BIOCEPT INC非执行主席至2020年10月。他是Hale BioPharma Ventures LLC(一家专注于生物技术、专业制药、诊断和医疗设备公司的形成和发展的私人公司)的董事长兼首席执行官。他是一名连续企业家，参与了许多生命科学公司的创立和/或发展。自2004年以来，他担任Santarus, Inc.(或Santarus，一家专业生物制药公司)的董事长;自2000年以来，担任Santarus的董事会成员(2014年被Salix Pharmaceuticals, Ltd.收购)。他还曾担任Conatus Pharmaceuticals, Inc.的董事长，直到该公司于2020年与Histogen合并。他曾担任CancerVax Corporation的总裁兼首席执行官(从1999年10月到2006年5月与Micromet, Inc.合并)，当时他成为合并后公司的董事长，直到该公司被Merck & Co.收购。他是Somaxon Pharmaceuticals, Inc.(被Pernix Therapeutics Holdings, Inc.收购)的联合创始人兼董事长，以及SkinMedica, Inc.(被Allergan, Inc.收购)的董事长。他还担任Adigica Health, Inc.、Zerigo Health, Inc.、Neurana Pharmaceuticals, Inc.和Dermata, LLC的董事长，以及Recros Medica, Inc.和Neurelis, Inc.的董事会成员。他曾担任Hybritech, Inc.(第一家单克隆抗体公司，自1982年起被Eli Lilly and Co.收购)的首席运营官、总裁兼首席执行官。从1987年到1997年，他担任Gensia, Inc.(与SICOR合并成为Gensia SICOR, Inc.)的董事长、总裁兼首席执行官，Gensia SICOR, Inc.后来被Teva Pharmaceuticals收购。1987年至1995年，他是Viagene, Inc.的联合创始人兼董事长，当时Viagene被Chiron, Inc.收购。1998年至1999年6月，他担任Women First HealthCare, Inc.的总裁兼首席执行官，1999年10月加入CancerVax。在加入Hybritech之前，他曾担任Becton, Dickinson & Co.的诊断部门BBL Microbiology Systems的副总裁兼总经理，从1971年到1980年，他曾担任Ortho Pharmaceutical Corporation (Johnson & Johnson, Inc.的一个部门)的各种营销和销售管理职位。
- David F. Hale was appointed as BIOCEPT INC Executive Chairman in March 2011. As of and in connection with the closing of BIOCEPT INC initial public offering on February 10 2014 Mr. Hale served as BIOCEPT INC non-executive chairman through October 2020. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences companies. He served as the Chairman of Santarus, Inc., or Santarus, a specialty biopharmaceutical company, since 2004 and a member of Santarus' board since 2000 prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014. He also served as Chairman of Conatus Pharmaceuticals, Inc. until its merger with Histogen in 2020 and serves as Chairman of Oncternal Therapeutics, Inc. He was previously President and CEO of CancerVax Corporation from October 1999 through its merger in May 2006 with Micromet, Inc., when he became Chairman of the combined company until its acquisition by Merck & Co. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc., and as Chairman of SkinMedica, Inc., before its acquisition by Allergan, Inc. He also serves as Chairman of Adigica Health, Inc., Zerigo Health, Inc., Neurana Pharmaceuticals, Inc., and Dermata, LLC and is on the board of Recros Medica, Inc. and Neurelis, Inc. He served as COO, President and Chief Executive Officer of Hybritech, Inc., the first monoclonal antibody company, from 1982 it was acquired by Eli Lilly and Co. in 1986. From 1987 until 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was later acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995 when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc. from 1998 to June 1999 before joining CancerVax in October 1999. Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a diagnostics division of Becton, Dickinson & Co. and from 1971 to 1980 he held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.
- Daniel L. Kisner
-
Daniel L. Kisner， 2014年2月起担任Conatus董事会成员。他目前担任生命科学行业的独立顾问。2003年至2011年，他是Aberdare Ventures的合伙人。2002年至2008年，他担任Caliper Life Sciences的董事会主席；1999年至2002年，他担任其前身公司Caliper Technologies的总裁兼首席执行官。从1991年到1999年，他在Isis Pharmaceuticals, Inc.担任越来越重要的职位，最近担任总裁兼首席运营官。1988年至1991年，他在Abbott Laboratories和SmithKline Beckman实验室（SmithKline Beckman Laboratories）担任药物研究和开发行政职务。他曾担任Texas大学， San Antonio School of Medicine的肿瘤学部门的终身教授，直到1985年，此前他在the National Cancer Institute的癌症治疗评估项目（Cancer Treatment Evaluation Program）工作了五年。Kisner博士获得内科和肿瘤医学委员会认证。他持有Rutgers大学的学士学位和Georgetown大学的医学博士学位。他目前担任Zynerba Pharmaceuticals、Dynavax Technologies Corporation和Oncternal Therapeutics的董事，并拥有广泛的私人和上市公司董事会经验，包括担任Tekmira Pharmaceuticals的董事会主席。
Daniel L. Kisner,has been a member of Board since July 2010. From 2003 to 2010, Dr. Kisner served as a partner at Aberdare Ventures and prior to that as President and Chief Executive Officer of Caliper Technologies, leading its evolution from a start-up focused on microfluidic lab-on-chip technology to a publicly traded, commercial organization. Prior to Caliper, he was the President and Chief Operating Officer of Isis Pharmaceuticals, Inc., a biomedical pharmaceutical company. Previously, Dr. Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Additionally, he is currently serving on the board of Oncternal Therapeutics, Inc., a San Diego based cancer therapeutics company. Dr. Kisner previously served as Chairman of the board for Tekmira Pharmaceuticals, a biopharmaceutical company, until March 2015, and as a director of Histogen, Inc., Lpath, Inc., Conatus Pharmaceuticals and Zynerba Pharmaceuticals. He holds a B.A. from Rutgers University and an M.D. from Georgetown University. - Daniel L. Kisner， 2014年2月起担任Conatus董事会成员。他目前担任生命科学行业的独立顾问。2003年至2011年，他是Aberdare Ventures的合伙人。2002年至2008年，他担任Caliper Life Sciences的董事会主席；1999年至2002年，他担任其前身公司Caliper Technologies的总裁兼首席执行官。从1991年到1999年，他在Isis Pharmaceuticals, Inc.担任越来越重要的职位，最近担任总裁兼首席运营官。1988年至1991年，他在Abbott Laboratories和SmithKline Beckman实验室（SmithKline Beckman Laboratories）担任药物研究和开发行政职务。他曾担任Texas大学， San Antonio School of Medicine的肿瘤学部门的终身教授，直到1985年，此前他在the National Cancer Institute的癌症治疗评估项目（Cancer Treatment Evaluation Program）工作了五年。Kisner博士获得内科和肿瘤医学委员会认证。他持有Rutgers大学的学士学位和Georgetown大学的医学博士学位。他目前担任Zynerba Pharmaceuticals、Dynavax Technologies Corporation和Oncternal Therapeutics的董事，并拥有广泛的私人和上市公司董事会经验，包括担任Tekmira Pharmaceuticals的董事会主席。
- Daniel L. Kisner,has been a member of Board since July 2010. From 2003 to 2010, Dr. Kisner served as a partner at Aberdare Ventures and prior to that as President and Chief Executive Officer of Caliper Technologies, leading its evolution from a start-up focused on microfluidic lab-on-chip technology to a publicly traded, commercial organization. Prior to Caliper, he was the President and Chief Operating Officer of Isis Pharmaceuticals, Inc., a biomedical pharmaceutical company. Previously, Dr. Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Additionally, he is currently serving on the board of Oncternal Therapeutics, Inc., a San Diego based cancer therapeutics company. Dr. Kisner previously served as Chairman of the board for Tekmira Pharmaceuticals, a biopharmaceutical company, until March 2015, and as a director of Histogen, Inc., Lpath, Inc., Conatus Pharmaceuticals and Zynerba Pharmaceuticals. He holds a B.A. from Rutgers University and an M.D. from Georgetown University.
高管简历
中英对照 | 中文 | 英文- Chase C. Leavitt
Chase C.Leavitt于2019年5月加入Lineage，担任总法律顾问兼公司秘书。在加入Leavitt之前，Leavitt先生曾担任Tang Capital Management，LLC（一家专注于生命科学的投资公司）及其附属公司OdonateTherapeutics，Inc.的法律事务Vice PresidentODT，一家公开交易的生物技术公司，于2018年6月至2019年5月。从2017年5月至2018年5月，Leavitt先生曾担任Switch，Inc.（SWCH）（一家公开上市的技术公司）的副总法律顾问，并曾于2014年7月至2017年5月担任其副总法律顾问。从2007年到2014年，他曾担任Latham&Watkins公司的公司律师，在那里他的实践专注于上市公司代表、并购和资本市场，服务生命科学和技术公司。Leavitt先生在南加州大学（University of Southern California）获得工商管理学士学位和法学博士学位，并被加州律师协会（State Bar of California）录取从事法律执业。
Chase C. Leavitt joined Lineage as General Counsel and Corporate Secretary in May 2019. Prior to joining Lineage, Mr. Leavitt served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc. ODT, a publicly traded biotechnology company, from June 2018 to May 2019. From May 2017 to May 2018 Mr. Leavitt served as the Deputy General Counsel of Switch, Inc. (SWCH), a publicly traded technology company, and previously served as its Associate General Counsel from July 2014 to May 2017. From 2007 to 2014 Mr. Leavitt was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and capital markets, serving life sciences and technology companies. Mr. Leavitt received a B.S. degree in business administration and a J.D. from the University of Southern California and is admitted to practice law by the State Bar of California.- Chase C.Leavitt于2019年5月加入Lineage，担任总法律顾问兼公司秘书。在加入Leavitt之前，Leavitt先生曾担任Tang Capital Management，LLC（一家专注于生命科学的投资公司）及其附属公司OdonateTherapeutics，Inc.的法律事务Vice PresidentODT，一家公开交易的生物技术公司，于2018年6月至2019年5月。从2017年5月至2018年5月，Leavitt先生曾担任Switch，Inc.（SWCH）（一家公开上市的技术公司）的副总法律顾问，并曾于2014年7月至2017年5月担任其副总法律顾问。从2007年到2014年，他曾担任Latham&Watkins公司的公司律师，在那里他的实践专注于上市公司代表、并购和资本市场，服务生命科学和技术公司。Leavitt先生在南加州大学（University of Southern California）获得工商管理学士学位和法学博士学位，并被加州律师协会（State Bar of California）录取从事法律执业。
- Chase C. Leavitt joined Lineage as General Counsel and Corporate Secretary in May 2019. Prior to joining Lineage, Mr. Leavitt served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences-focused investment company, and its affiliate Odonate Therapeutics, Inc. ODT, a publicly traded biotechnology company, from June 2018 to May 2019. From May 2017 to May 2018 Mr. Leavitt served as the Deputy General Counsel of Switch, Inc. (SWCH), a publicly traded technology company, and previously served as its Associate General Counsel from July 2014 to May 2017. From 2007 to 2014 Mr. Leavitt was a corporate attorney at Latham & Watkins LLP, where his practice focused on public company representation, mergers and acquisitions and capital markets, serving life sciences and technology companies. Mr. Leavitt received a B.S. degree in business administration and a J.D. from the University of Southern California and is admitted to practice law by the State Bar of California.
- Gunnar F. Kaufmann
Gunnar F. Kaufmann，自2019年9月起担任Oncternal Therapeutics, Inc.首席科学官。Kaufmann博士在生物治疗和小分子药物候选产品的发现和临床前开发方面拥有丰富的经验，并负责推进Oncternal医疗公司的临床前产品开发计划，并探索扩大Oncternal医疗公司产品开发管道的机会。在加入Oncternal Therapeutics, Inc.之前，Kaufmann博士曾于2014年10月至2019年9月担任索伦托医疗公司免疫治疗高级副总裁、研究和全球伙伴关系主管。考夫曼博士以前是斯克里普斯研究所的教员，现在仍然担任化学、免疫学和微生物科学系的兼职助理教授。考夫曼博士拥有菲利普斯大学马尔堡分校的人类生物学学士学位、恩斯特-莫里茨-阿恩特大学格赖夫斯瓦尔德分校的人类生物学硕士学位，以及斯克里普斯研究所生物学项目的博士学位。
Gunnar F. Kaufmann,has served as Oncternal Therapeutics, Inc. Chief Scientific Officer since September 2019. Dr. Kaufmann has extensive experience in discovery and preclinical development of both biotherapeutics and small molecule drug product candidates and is responsible for progressing Oncternal Therapeutics, Inc. preclinical product development programs and exploring opportunities to expand Oncternal Therapeutics, Inc. product development pipeline. Prior to joining Oncternal Therapeutics, Inc. , Dr. Kaufmann served as Senior Vice President, Immunotherapy, Head of Research and Global Partnerships at Sorrento Therapeutics, Inc. from October 2014 to September 2019. Dr. Kaufmann was previously a faculty member at The Scripps Research Institute and still serves as Adjunct Assistant Professor in the Departments of Chemistry and Immunology and Microbial Science. Dr. Kaufmann holds a B.S. in human biology from Phillips University Marburg, an M.S. in human biology from Ernst-Moritz-Arndt University Greifswald, and a Ph.D. from The Scripps Research Institute's Biology Program.- Gunnar F. Kaufmann，自2019年9月起担任Oncternal Therapeutics, Inc.首席科学官。Kaufmann博士在生物治疗和小分子药物候选产品的发现和临床前开发方面拥有丰富的经验，并负责推进Oncternal医疗公司的临床前产品开发计划，并探索扩大Oncternal医疗公司产品开发管道的机会。在加入Oncternal Therapeutics, Inc.之前，Kaufmann博士曾于2014年10月至2019年9月担任索伦托医疗公司免疫治疗高级副总裁、研究和全球伙伴关系主管。考夫曼博士以前是斯克里普斯研究所的教员，现在仍然担任化学、免疫学和微生物科学系的兼职助理教授。考夫曼博士拥有菲利普斯大学马尔堡分校的人类生物学学士学位、恩斯特-莫里茨-阿恩特大学格赖夫斯瓦尔德分校的人类生物学硕士学位，以及斯克里普斯研究所生物学项目的博士学位。
- Gunnar F. Kaufmann,has served as Oncternal Therapeutics, Inc. Chief Scientific Officer since September 2019. Dr. Kaufmann has extensive experience in discovery and preclinical development of both biotherapeutics and small molecule drug product candidates and is responsible for progressing Oncternal Therapeutics, Inc. preclinical product development programs and exploring opportunities to expand Oncternal Therapeutics, Inc. product development pipeline. Prior to joining Oncternal Therapeutics, Inc. , Dr. Kaufmann served as Senior Vice President, Immunotherapy, Head of Research and Global Partnerships at Sorrento Therapeutics, Inc. from October 2014 to September 2019. Dr. Kaufmann was previously a faculty member at The Scripps Research Institute and still serves as Adjunct Assistant Professor in the Departments of Chemistry and Immunology and Microbial Science. Dr. Kaufmann holds a B.S. in human biology from Phillips University Marburg, an M.S. in human biology from Ernst-Moritz-Arndt University Greifswald, and a Ph.D. from The Scripps Research Institute's Biology Program.
- Salim Yazji
Salim Yazji，自2021年5月起担任Oncternal Therapeutics, Inc.首席医疗官。Yazji博士于2019年1月创立了Elpida Therapeutics，并于2019年10月与他人共同创立了Ajuta Therapeutics，担任首席执行官至2021年2月。自2019年4月起，他还担任Versatope Therapeutics的董事会成员。2018年3月至2019年1月，他担任PMV制药的首席医疗官，2016年11月至2018年2月，他担任Calimmune的执行副总裁兼首席医疗官，该公司于2017年8月被CSL Behring收购。在此之前，Yazji博士曾于2013年至2015年担任百特国际副总裁兼肿瘤科全球主管，并于2015年担任Baxalta的子公司，直到2016年7月被Shire plc收购。从2009年到2013年，他在诺华担任越来越重要的全球职务，领导多个肿瘤注册临床试验，最近担任高级全球临床领导。2009年之前，他曾在伊克力西斯、PDL生物制药和强生任职。Yazji博士在俄罗斯圣彼得堡圣彼得堡大学帕夫洛夫医学院获得医学博士学位，并在德克萨斯大学安德森癌症中心、休斯顿公园广场医院和俄罗斯圣彼得堡阿尔莫佐夫医院完成研究生培训。
Salim Yazji,has served as Oncternal Therapeutics, Inc. Chief Medical Officer since May 2021. Dr. Yazji founded Elpida Therapeutics in January 2019 and co-founded Ajuta Therapeutics in October 2019, where he served as Chief Executive Officer until February 2021. He has also served on the Board of Directors of Versatope Therapeutics since April 2019. From March 2018 to January 2019, he served as Chief Medical Officer of PMV Pharma, and from November 2016 to February 2018, he served as Executive Vice President and Chief Medical Officer of Calimmune, which was acquired by CSL Behring in August 2017. Prior to that, Dr. Yazji served as Vice President & Global Head of Oncology at Baxter International from 2013 to 2015 and its spinoff Baxalta from 2015 until it was acquired by Shire Plc in July 2016. From 2009 to 2013, he held global positions of increasing responsibility within Novartis where he led multiple oncology registrational clinical trials, most recently as Senior Global Clinical Leader. Prior to 2009, he held positions with Exelixis, PDL BioPharma, and Johnson & Johnson. Dr. Yazji obtained his MD from the Pavlov School of Medicine, University of St. Petersburg, St. Petersburg, Russia, and completed his post-graduate training at the University of Texas M.D. Anderson Cancer Center, Park Plaza Hospital, Houston and the Almozov Hospital, St. Petersburg, Russia.- Salim Yazji，自2021年5月起担任Oncternal Therapeutics, Inc.首席医疗官。Yazji博士于2019年1月创立了Elpida Therapeutics，并于2019年10月与他人共同创立了Ajuta Therapeutics，担任首席执行官至2021年2月。自2019年4月起，他还担任Versatope Therapeutics的董事会成员。2018年3月至2019年1月，他担任PMV制药的首席医疗官，2016年11月至2018年2月，他担任Calimmune的执行副总裁兼首席医疗官，该公司于2017年8月被CSL Behring收购。在此之前，Yazji博士曾于2013年至2015年担任百特国际副总裁兼肿瘤科全球主管，并于2015年担任Baxalta的子公司，直到2016年7月被Shire plc收购。从2009年到2013年，他在诺华担任越来越重要的全球职务，领导多个肿瘤注册临床试验，最近担任高级全球临床领导。2009年之前，他曾在伊克力西斯、PDL生物制药和强生任职。Yazji博士在俄罗斯圣彼得堡圣彼得堡大学帕夫洛夫医学院获得医学博士学位，并在德克萨斯大学安德森癌症中心、休斯顿公园广场医院和俄罗斯圣彼得堡阿尔莫佐夫医院完成研究生培训。
- Salim Yazji,has served as Oncternal Therapeutics, Inc. Chief Medical Officer since May 2021. Dr. Yazji founded Elpida Therapeutics in January 2019 and co-founded Ajuta Therapeutics in October 2019, where he served as Chief Executive Officer until February 2021. He has also served on the Board of Directors of Versatope Therapeutics since April 2019. From March 2018 to January 2019, he served as Chief Medical Officer of PMV Pharma, and from November 2016 to February 2018, he served as Executive Vice President and Chief Medical Officer of Calimmune, which was acquired by CSL Behring in August 2017. Prior to that, Dr. Yazji served as Vice President & Global Head of Oncology at Baxter International from 2013 to 2015 and its spinoff Baxalta from 2015 until it was acquired by Shire Plc in July 2016. From 2009 to 2013, he held global positions of increasing responsibility within Novartis where he led multiple oncology registrational clinical trials, most recently as Senior Global Clinical Leader. Prior to 2009, he held positions with Exelixis, PDL BioPharma, and Johnson & Johnson. Dr. Yazji obtained his MD from the Pavlov School of Medicine, University of St. Petersburg, St. Petersburg, Russia, and completed his post-graduate training at the University of Texas M.D. Anderson Cancer Center, Park Plaza Hospital, Houston and the Almozov Hospital, St. Petersburg, Russia.
- Rajesh Krishnan
Rajesh Krishnan自2021年1月起担任Oncternal Therapeutics, Inc.首席技术官，此前于2019年8月至2021年1月担任Oncternal Therapeutics, Inc. CMC和制造高级副总裁。从2018年1月至2019年8月，他在Dynavax Technologies Corporation担任工艺开发和制造科学副总裁，领导制造、药物工艺开发、工艺验证、分析科学以及商业和临床开发项目的技术转让工作，包括商业化的Heplisav B产品。从2012年到2017年，Krishnan博士曾在吉利德科学公司担任多个职位，最近担任生物制剂药物工艺开发总监，领导多个临床生物制剂项目的上下游工艺开发。从2000年到2012年，他在默克制药公司、安进公司和辉瑞担任越来越重要的职务，在工艺开发、技术转让以及临床和商业生物制剂项目的CMC方面发挥着一贯的领导作用。Krishnan博士拥有普林斯顿大学化学工程学士学位、加州大学戴维斯分校化学工程学硕士学位和加州大学戴维斯分校生物化学工程学博士学位。
Rajesh Krishnan,has served as Oncternal Therapeutics, Inc. Chief Technology Officer since January 2021 and previously served as Oncternal Therapeutics, Inc. Senior Vice President, CMC and Manufacturing, from August 2019 to January 2021. From January 2018 until August 2019, he served as Vice President, Process Development and Manufacturing Sciences at Dynavax Technologies Corporation, where he led manufacturing, drug process development, process validation, analytical sciences and technology transfer efforts for commercial and clinical development programs, including the commercial Heplisav B product. From 2012 through 2017, Dr. Krishnan served in several positions at Gilead Sciences, Inc., most recently as Director of Biologics Drug Substance Process Development, leading upstream and downstream process development for multiple clinical biologics programs. From 2000 to 2012, he served in positions of increasing responsibility at Merck & Co., Inc., Amgen Inc. and Pfizer, with a consistent leadership role across process development, technology transfer and CMC for clinical and commercial biologics programs. Dr. Krishnan holds a B.S.E. degree in chemical engineering from Princeton University, a M.S. degree in chemical engineering from the University of California, Davis, and a Ph.D. degree in Biochemical Engineering from the University of California, Davis.- Rajesh Krishnan自2021年1月起担任Oncternal Therapeutics, Inc.首席技术官，此前于2019年8月至2021年1月担任Oncternal Therapeutics, Inc. CMC和制造高级副总裁。从2018年1月至2019年8月，他在Dynavax Technologies Corporation担任工艺开发和制造科学副总裁，领导制造、药物工艺开发、工艺验证、分析科学以及商业和临床开发项目的技术转让工作，包括商业化的Heplisav B产品。从2012年到2017年，Krishnan博士曾在吉利德科学公司担任多个职位，最近担任生物制剂药物工艺开发总监，领导多个临床生物制剂项目的上下游工艺开发。从2000年到2012年，他在默克制药公司、安进公司和辉瑞担任越来越重要的职务，在工艺开发、技术转让以及临床和商业生物制剂项目的CMC方面发挥着一贯的领导作用。Krishnan博士拥有普林斯顿大学化学工程学士学位、加州大学戴维斯分校化学工程学硕士学位和加州大学戴维斯分校生物化学工程学博士学位。
- Rajesh Krishnan,has served as Oncternal Therapeutics, Inc. Chief Technology Officer since January 2021 and previously served as Oncternal Therapeutics, Inc. Senior Vice President, CMC and Manufacturing, from August 2019 to January 2021. From January 2018 until August 2019, he served as Vice President, Process Development and Manufacturing Sciences at Dynavax Technologies Corporation, where he led manufacturing, drug process development, process validation, analytical sciences and technology transfer efforts for commercial and clinical development programs, including the commercial Heplisav B product. From 2012 through 2017, Dr. Krishnan served in several positions at Gilead Sciences, Inc., most recently as Director of Biologics Drug Substance Process Development, leading upstream and downstream process development for multiple clinical biologics programs. From 2000 to 2012, he served in positions of increasing responsibility at Merck & Co., Inc., Amgen Inc. and Pfizer, with a consistent leadership role across process development, technology transfer and CMC for clinical and commercial biologics programs. Dr. Krishnan holds a B.S.E. degree in chemical engineering from Princeton University, a M.S. degree in chemical engineering from the University of California, Davis, and a Ph.D. degree in Biochemical Engineering from the University of California, Davis.
- James B. Breitmeyer
James B. Breitmeyer，2006年8月起，担任本公司的开发执行副总裁、首席医学官。2001年12月至2006年8月，他担任Applied Molecular Evolution的首席医学官、制药业务副总裁，这是全球性制药公司Eli Lilly and Company的全资子公司。2000年2月至2001年7月，他是Harvard Clinical Research Institute的总裁、首席执行官。2000年2月之前，他在全球性生物制药公司Serono International S.A.担任了愈益重要的各种职务，其中包括高级副总裁、首席医学官。他在University of California, Santa Cruz获得化学学士学位，在Washington University School of Medicine获得医学博士学位、博士学位。
James B. Breitmeyer, M.D., Ph.D. has served as a member of ZOGENIX, INC. board of directors since March 2014. Since August 2015 Dr. Breitmeyer has served as President, CEO and Director of Oncternal Therapeutics, Inc. a clinical-stage oncology biotechnology company. Previously, he served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian A/S, a multinational corporation headquartered in Denmark, from February 2013 to July 2015. He previously served as the acting Chief Medical Officer of Zogenix Inc. from August 2012 to February 2013 in an advisory capacity, the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., from August 2006 to August 2012 and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. from December 2001 to August 2006. Dr. Breitmeyer has also served as President and Chief Executive Officer of the Harvard Clinical Research Institute and held a variety of positions at Serono Laboratories Inc. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer earned his B.A. in Chemistry from the University of California, Santa Cruz and his M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology.- James B. Breitmeyer，2006年8月起，担任本公司的开发执行副总裁、首席医学官。2001年12月至2006年8月，他担任Applied Molecular Evolution的首席医学官、制药业务副总裁，这是全球性制药公司Eli Lilly and Company的全资子公司。2000年2月至2001年7月，他是Harvard Clinical Research Institute的总裁、首席执行官。2000年2月之前，他在全球性生物制药公司Serono International S.A.担任了愈益重要的各种职务，其中包括高级副总裁、首席医学官。他在University of California, Santa Cruz获得化学学士学位，在Washington University School of Medicine获得医学博士学位、博士学位。
- James B. Breitmeyer, M.D., Ph.D. has served as a member of ZOGENIX, INC. board of directors since March 2014. Since August 2015 Dr. Breitmeyer has served as President, CEO and Director of Oncternal Therapeutics, Inc. a clinical-stage oncology biotechnology company. Previously, he served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian A/S, a multinational corporation headquartered in Denmark, from February 2013 to July 2015. He previously served as the acting Chief Medical Officer of Zogenix Inc. from August 2012 to February 2013 in an advisory capacity, the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., from August 2006 to August 2012 and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. from December 2001 to August 2006. Dr. Breitmeyer has also served as President and Chief Executive Officer of the Harvard Clinical Research Institute and held a variety of positions at Serono Laboratories Inc. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer earned his B.A. in Chemistry from the University of California, Santa Cruz and his M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology.
- Richard G. Vincent
Richard G. Vincent于2010年1月加入Sorrento Therapeutics, Inc.，并担任Sorrento Therapeutics, Inc.的董事。从2010年2月到2012年9月，担任兼职首席财务官，并担任Sorrento Therapeutics, Inc.的首席财务官。自2012年9月起担任全职首席财务官。从2004年10月到2009年3月，他担任Verus Pharmaceuticals的首席财务官，这是一家专业制药公司，专注于开发和商业化儿科药物/设备组合产品，用于治疗哮喘、过敏、以及相关的疾病和状况。从2003年10月到2004年10月，他担任Women First HealthCare（一家专注于女性医疗保健和皮肤病的公共专业制药公司）的首席财务官。2001年10月至2003年10月，他还担任Elan Pharmaceuticals（一家公共生物制药公司，主要从事神经科学、自身免疫和严重慢性疼痛方面的研究、开发和商业活动）的高级财务总监。从1995年11月到2001年10月，Vincent先生在几家无线和技术公司担任各种高级管理职务。从1987年到1995年，Vincent先生在Deloitte & Touche LLP担任多个职位，最后一个职位是高级经理，在那里他专门从事新兴增长和公开报告公司。他于1989年成为加利福尼亚州的注册会计师，并持有圣地亚哥州立大学（San Diego State University）的商业学士学位，主修会计。
Richard G. Vincent joined Sorrento Therapeutics, Inc. in January 2010 and served as Sorrento Therapeutics, Inc. Chief Financial Officer, on a part-time basis, from February 2010 to September 2012 and has served as Sorrento Therapeutics, Inc. Chief Financial Officer on a full time basis since September 2012. Since April 2008 Mr. Vincent has also served as a contract Chief Financial Officer for various other companies, including Elevation Pharmaceuticals, Meritage Pharma, Genoa Pharmaceuticals, Verus Pharmaceuticals, and Suneva Medical From October 2004 to March 2009 Mr. Vincent served as Chief Financial Officer of Verus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing pediatric drug/device combination products for the treatment of asthma, allergies, and related diseases and conditions. From October 2003 to October 2004 Mr. Vincent served as Chief Financial Officer of Women First HealthCare, a public specialty pharmaceutical company focused on women's healthcare and dermatology. Mr. Vincent also served as Senior Director of Finance for Elan Pharmaceuticals, a public biopharmaceutical company engaged in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain, from October 2001 to October 2003. From November 1995 to October 2001 Mr. Vincent served in various senior management capacities for several wireless and technology companies. From 1987 to 1995 Mr. Vincent held a number of positions with Deloitte & Touche LLP, the last of which was senior manager, where he specialized in emerging growth and publicly-reporting companies. Mr. Vincent became a Certified Public Accountant in California in 1989 and holds a B.S. degree in business with an emphasis in accounting from San Diego State University.- Richard G. Vincent于2010年1月加入Sorrento Therapeutics, Inc.，并担任Sorrento Therapeutics, Inc.的董事。从2010年2月到2012年9月，担任兼职首席财务官，并担任Sorrento Therapeutics, Inc.的首席财务官。自2012年9月起担任全职首席财务官。从2004年10月到2009年3月，他担任Verus Pharmaceuticals的首席财务官，这是一家专业制药公司，专注于开发和商业化儿科药物/设备组合产品，用于治疗哮喘、过敏、以及相关的疾病和状况。从2003年10月到2004年10月，他担任Women First HealthCare（一家专注于女性医疗保健和皮肤病的公共专业制药公司）的首席财务官。2001年10月至2003年10月，他还担任Elan Pharmaceuticals（一家公共生物制药公司，主要从事神经科学、自身免疫和严重慢性疼痛方面的研究、开发和商业活动）的高级财务总监。从1995年11月到2001年10月，Vincent先生在几家无线和技术公司担任各种高级管理职务。从1987年到1995年，Vincent先生在Deloitte & Touche LLP担任多个职位，最后一个职位是高级经理，在那里他专门从事新兴增长和公开报告公司。他于1989年成为加利福尼亚州的注册会计师，并持有圣地亚哥州立大学（San Diego State University）的商业学士学位，主修会计。
- Richard G. Vincent joined Sorrento Therapeutics, Inc. in January 2010 and served as Sorrento Therapeutics, Inc. Chief Financial Officer, on a part-time basis, from February 2010 to September 2012 and has served as Sorrento Therapeutics, Inc. Chief Financial Officer on a full time basis since September 2012. Since April 2008 Mr. Vincent has also served as a contract Chief Financial Officer for various other companies, including Elevation Pharmaceuticals, Meritage Pharma, Genoa Pharmaceuticals, Verus Pharmaceuticals, and Suneva Medical From October 2004 to March 2009 Mr. Vincent served as Chief Financial Officer of Verus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing pediatric drug/device combination products for the treatment of asthma, allergies, and related diseases and conditions. From October 2003 to October 2004 Mr. Vincent served as Chief Financial Officer of Women First HealthCare, a public specialty pharmaceutical company focused on women's healthcare and dermatology. Mr. Vincent also served as Senior Director of Finance for Elan Pharmaceuticals, a public biopharmaceutical company engaged in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain, from October 2001 to October 2003. From November 1995 to October 2001 Mr. Vincent served in various senior management capacities for several wireless and technology companies. From 1987 to 1995 Mr. Vincent held a number of positions with Deloitte & Touche LLP, the last of which was senior manager, where he specialized in emerging growth and publicly-reporting companies. Mr. Vincent became a Certified Public Accountant in California in 1989 and holds a B.S. degree in business with an emphasis in accounting from San Diego State University.